INVESTIGATION ALERT: Edelson Lechtzin LLP Announces An Investigation Of Lantheus Holdings, Inc. (NASDAQ: LNTH) And Encourages Investors With Substantial Losses To Contact The Firm

(MENAFN- PR Newswire)

NEWTOWN, Pa., Sept. 11, 2025 /PRNewswire/ -- Edelson Lechtzin LLP is investigating potential violations of the federal securities laws involving Lantheus Holdings, Inc. ("Lantheus") (NASDAQ: LNTH ), resulting from allegations of providing potentially misleading business information to the investing public.

If you have information that could assist in the Lantheus investigation or if you are a Lantheus investor who suffered a loss and would like to learn more, you can provide your information HERE .

You can also contact attorney Eric Lechtzin of Edelson Lechtzin LLP by calling 844-563-5550 or via e-mail at [email protected] .

ABOUT THE COMPANY: Lantheus Holdings, Inc. is a globally recognized company focused on the development, production, and distribution of advanced diagnostic and therapeutic products, with core expertise in oncology and cardiovascular care.

THE ALLEGED WRONGDOING: On August 6, 2025, Lantheus reported weaker-than-expected second-quarter results, missing earnings and revenue targets. The company also cut its full-year 2025 revenue and EPS forecasts, citing tougher competition in the PSMA PET imaging market and strategic pullbacks from certain accounts. Revenue for the quarter fell to $378 million, down 4.1%, with PYLARIFY sales dropping 8.3% to $250.6 million-both below projections.

On this news, the price of Lantheus stock fell $20.76 per share, or 28.58%, to close at $51.87 per share on August 6, 2025.

ABOUT EDELSON LECHTZIN LLP: Edelson Lechtzin LLP is a national class action law firm with offices in Pennsylvania and California. In addition to cases involving securities and investment fraud, our lawyers focus on class and collective litigation in cases alleging violations of the federal antitrust laws, employee benefit plans under ERISA, wage theft and unpaid overtime, consumer fraud, and dangerous and defective drugs and medical devices.

For more information, please contact:

Eric Lechtzin, Esq.
EDELSON LECHTZIN LLP
411 S. State Street, Suite N-300
Newtown, PA 18940
Phone: 844-696-7492 or 215-867-2399 ext. 1
Email: [email protected]
Web:

This press release may be considered Attorney Advertising in some jurisdictions. No class has been certified in this case, so you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. Your ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

SOURCE Edelson Lechtzin LLP

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE? 440k+
Newsrooms &
Influencers 9k+
Digital Media
Outlets 270k+
Journalists
Opted In GET STARTED

MENAFN11092025003732001241ID1110051684